Merck Stock News

JPMorgan analyst Chris Schott lowered the firm''s price target ((PT)) on Merck (MRK) to $95 from $100 and keeps an Overweight rating ahead of the company''s Q4 results. The company

Merck (MRK) and Ridgeback Biotherapeutics, its partner in the development of the FDA-authorized COVID-19 therapy, molnupiravir announced that the oral medication was found to be

COVID-19 Can Be Stopped Without Massive Vaccination: Dr. Peter McCullough Authored by Harry Lee and Steve Lance via The Epoch Times (emphasis ours), COVID-19 can be stopped without massive vaccination, renowned cardiologist and epidemiologist Dr. Peter McCullough told NTDs Capitol Report program during the Defeat the Mandates march in Washington D.C., on Jan. 23. According to McCullough, early treatment and natural immunity are safe and effective against COVID-19, but federal health agencies have ignored these in a push for vaccines, the broad use of which is not needed. The government has certainly been in an oblivion in terms of early treatment, he said. Thousands of people turned out to march in protest against COVID-19 vaccine mandatesone of the largest U.S. events against the mandates since the start of the pandemic. Our CDC, FDA, and NIH have had no effective messaging on early treatment, even the emergency use authorized monoclonal antibodies, which are safe and effective, McCullough said. And even on the new Merck and Pfizer drugs, which theyre basically absent in terms of the media, despite being recently distributed across the United States. Early effective treatment of any disease can help avert progression to more serious illness, with an additional benefit of reducing the burden on health care systems, and in a seperate interview, McCullough claimed that 95% of the COVID deaths could have been prevented by early treatment

Researchers say that Merck blockbuster oncology drug Keytruda may also have an effect against HIV.

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

Merck (MRK) announced that the European Commission approved KEYTRUDA as monotherapy for adjuvant treatment for a certain category of patients with renal cell carcinoma

Doctor''s Organization Has Treated Over 150,000 COVID-19 Patients With 99.99% Survival Authored by Meiling Lee via The Epoch Times (emphasis ours), A doctor who has been offering free telehealth services to COVID-19 patients during the pandemic says that early treatment for COVID-19 works, claiming that he has a 99.99 percent survival rate. “We have a team of volunteer free doctors that donate their time to help treat these patients that come to us,” Dr. Ben Marble, the founder of myfreedoctor.com, an online medical consultation service, said at a roundtable discussion hosted by Sen. Ron Johnson (R-Wis.) on Jan. 24. He added, “ We deliver the early treatment protocols to them as early as we can, and we have a 99.99 percent survival rate. So, I believe myfreedoctor.com, the free volunteered doctors have settled the science on this—early treatment works, period!” A paramedic prepares an ambulance at Hudson Regional Hospital in Secaucus, N.J., on Dec. 11, 2020. (Kena Betancur/AFP via Getty Images) Marble was answering Johnson’s question about what people can do if they or their loved ones have COVID-19.

Merck has been in the news quite bit lately with its new COVID-19 pill, but is the therapy enough to make the Big Pharma play a buy?

After Merck <> announced that the FDA rejected its marketing application for gefapixant as a treatment for adults with chronic cough, H.C

Merck (MRK) declares $0.69/share quarterly dividend, in line with previous.

"Indefensible Edict" - DeSantis Rages After Biden''s FDA Restricts Use Of Monoclonal Antibody Treatments Governor Ron DeSantis is demanding the Biden Administration reverse its sudden decision to revoke emergency use authorization (EUA) for monoclonal antibody treatments. In a statement from the Florida Governor''s office , he rages that this abrupt and unilateral action by the Biden Administration will prevent access to lifesaving treatments for Floridians and Americans. Without a shred of clinical data to support this action, Biden has forced trained medical professionals to choose between treating their patients or breaking the law, said Governor Ron DeSantis. This indefensible edict takes treatment out of the hands of medical professionals and will cost some Americans their lives. There are real-world implications to Bidens medical authoritarianism Americans access to treatments is now subject to the whims of a failing president. Rather than giving Americans the option for various COVID treatments, the FDA and the Biden Administration issued their royal decree, taking away the very thing that is proven to reduce hospitalizations and save lives, said Lieutenant Governor Jeanette Nuñez. Monoclonal antibody treatments like Regeneron have had a positive impact for thousands of Floridians.

eFFECTOR Therapeutics Inc (NASDAQ: EFTR ) entered into an investment agreement with Lincoln Park Capital for up to $50 million over 36 months . The Company said a new group was added to evaluate frontline maintenance in patients with PD-L1 1% in the Phase 2b KICKSTART trial of tomivosertib combined with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab) for non-small cell lung cancer Full story available on Benzinga.com

Pune, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Global Pharmaceutical & Biotechnology Environmental Monitoring Market Analysis and Insights : The global Pharmaceutical & Biotechnology Environmental Monitoring market size is projected to reach USD 1326.4 million by 2027, from USD 888 million in 2020, at a CAGR of 5.9% during 2021-2027 . Global " Pharmaceutical & Biotechnology Environmental Monitoring Market " Research Report provides vital evaluation accessible status of the Pharmaceutical & Biotechnology Environmental Monitoring with finest statistical data points, qualified feelings, definition, meaning, SWOT examination, and the most recent developments worldwide. It also includes estimates based on an acceptable set of expectations and processes. The research takes into account the revenue generated by This Report''s sales as well as improvements made by various application segments. The assessment report examines and provides information based on advertise segments such as geologies, applications, and industries.

The FDA has issued a Complete Response Letter (CRL) to Merck Co & Inc''s (NYSE: MRK ) gefapixant for refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. Gefapixant is an investigational, non-narcotic, orally administered selective P2X3 Full story available on Benzinga.com